<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="Anti-VEGF agents in metastatic colorectal cancer Fellow 1 林協霆 Supervisor 黃國埕醫師  What is anti-vascular endothelial growth factor (VEGF) :::columns"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=Anti-VEGF agents in metastatic colorectal cancer"><title>Anti-VEGF agents in metastatic colorectal cancer</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.440c12afe56c47722e71383f56d9f8f0.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.9d824aa930866f2c31941e3db882301d.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Anti-VEGF agents in metastatic colorectal cancer</h1><p class=meta>最後更新於
Sep 18, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/Anti-VEGF%20agents%20in%20metastatic%20colorectal%20cancer.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>📒目錄</summary><nav id=TableOfContents><ol><li><ol><li></li></ol></li><li><a href=#what-is-anti-vascular-endothelial-growth-factor-vegf>What is anti-vascular endothelial growth factor (VEGF)</a></li><li><a href=#overview-of-angiogenesis-inhibitors>Overview of angiogenesis inhibitors</a></li></ol><ol><li><ol><li><a href=#esmo-2023-mcrc>ESMO 2023 mCRC</a></li><li><a href=#esmo-2023-mcrc-1>ESMO 2023 mCRC</a></li><li><a href=#esmo-2023-mcrc-2>ESMO 2023 mCRC</a></li><li><a href=#esmo-2023-mcrc-3>ESMO 2023 mCRC</a></li></ol></li></ol><ol><li><ol><li><a href=#pretreatment-assessment-and-screening>Pretreatment assessment and screening</a></li><li><a href=#monitoring-during-treatment>Monitoring during treatment</a></li></ol></li><li><a href=#risk-factors-for-adverse-consequences-of-high-blood-pressure-bp>Risk factors for adverse consequences of high blood pressure (BP)</a><ol><li><a href=#established-or-subclinical-renal-disease-including>Established or subclinical renal disease including</a></li><li><a href=#three-or-more-of-the-following-cv-risk-factors>Three or more of the following CV risk factors</a></li><li><a href=#bevacizumab-avastin>Bevacizumab (Avastin)</a></li></ol></li><li><a href=#warnings>Warnings</a><ol><li><a href=#gi-perforation>GI Perforation</a></li><li><a href=#surgery-and-wound-healing-complications>Surgery and Wound Healing Complications</a></li><li><a href=#hemorrhage>Hemorrhage</a></li><li><a href=#sensitivity-reactions>Sensitivity Reactions</a></li><li><a href=#thromboembolism>Thromboembolism</a></li><li><a href=#hypertension>Hypertension</a></li><li><a href=#reversible-posterior-leukoencephalopathy-syndrome-rpls>Reversible Posterior Leukoencephalopathy Syndrome (RPLS)</a></li><li><a href=#proteinuria>Proteinuria</a></li><li><a href=#ovarian-failure>Ovarian Failure</a></li><li><a href=#neutropenia-and-infection>Neutropenia and Infection</a></li><li><a href=#chf>CHF</a></li><li><a href=#microangiopathic-hemolytic-anemia>Microangiopathic Hemolytic Anemia</a></li><li><a href=#ocular-effects>Ocular Effects</a></li></ol></li><li><a href=#as-first-line-therapy-bevacizumab-may-be-given-with>As first-line therapy, bevacizumab may be given with</a></li><li><a href=#bevacizumab-plus-irinotecan-fluorouracil-and-leucovorin-for-metastatic-colorectal-cancer>Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</a><ol><li></li></ol></li><li><a href=#adding-bevacizumab-to-chemotherapy-for-metastatic-colorectal-cancer-pooled-analysis-of-randomized-controlled-trials>Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer: Pooled Analysis of Randomized Controlled Trials</a><ol><li><a href=#summary>Summary</a></li></ol></li><li><a href=#safety-and-efficacy-of-three-oxaliplatin-and-fluoropyrimidine-regimens-with-or-without-bevacizumab-as-first-line-treatment-for-metastatic-colorectal-cancer>Safety and Efficacy of Three Oxaliplatin and Fluoropyrimidine Regimens with or Without Bevacizumab as First-line Treatment for Metastatic Colorectal Cancer</a></li><li><a href=#efficacy-and-safety-of-bevacizumab-in-metastatic-colorectal-cancer-patients>Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer Patients</a></li><li><a href=#irinotecan-regimens>Irinotecan regimens</a></li><li><a href=#in-the-tribe-study-for-bevfolfoxiri>In the TRIBE study for Bev/FOLFOXIRI</a><ol><li></li></ol></li><li><a href=#comparison-of-chemotherapy-plus-bevacizumab-vs-cetuximab-in-first-line-treatment-for-metastatic-colorectal-cancer>Comparison of Chemotherapy plus Bevacizumab vs Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer</a></li><li><a href=#fire-3>FIRE-3</a><ol><li></li></ol></li><li><a href=#comparison-of-two-groups>Comparison of Two Groups</a></li><li><a href=#other-findings>Other Findings</a></li><li><a href=#summary-1>Summary</a></li><li><a href=#cetuximab-vs-bevacizumab-in-combination-with-chemotherapy-as-initial-biologic-therapy-for-advanced-or-metastatic-colorectal-cancer>Cetuximab vs Bevacizumab in Combination with Chemotherapy as Initial Biologic Therapy for Advanced or Metastatic Colorectal Cancer</a></li><li><a href=#results>Results</a></li><li><a href=#other-findings-1>Other findings</a></li><li><a href=#summary-2>Summary</a></li><li><a href=#paradigm>PARADIGM</a></li><li><a href=#as-maintenance-therapy-continued-use-of-bevacizumab-in-patients-with-metastatic-colorectal-cancer-progressing-after-standard-first-line-bevacizumab-based-treatment>As maintenance therapy: Continued use of bevacizumab in patients with metastatic colorectal cancer progressing after standard first-line bevacizumab-based treatment</a></li><li><a href=#agent>Agent</a></li><li><a href=#comparison-of-two-groups-1>Comparison of Two Groups</a></li><li><a href=#other-findings-2>Other Findings</a></li><li><a href=#summary-3>Summary</a></li><li><a href=#comparison-of-chemotherapy-plus-bevacizumab-vs-cetuximab-in-second-line-treatment-for-metastatic-colorectal-cancer>Comparison of Chemotherapy plus Bevacizumab vs Cetuximab in Second-Line Treatment for Metastatic Colorectal Cancer</a><ol><li><a href=#comparison-of-two-groups-2>Comparison of Two Groups</a></li><li><a href=#other-findings-3>Other Findings</a></li><li><a href=#summary-4>Summary</a></li></ol></li><li><a href=#bebyp-trial>BEBYP trial</a></li><li><a href=#whether-to-switch-to-cetuximab-or-continue-with-second-line-bevacizumab-in-patients-with-ras-wild-type-tumors-progressing-on-first-line-bevacizumab>whether to switch to cetuximab or continue with second-line bevacizumab in patients with RAS wild-type tumors progressing on first-line bevacizumab</a></li><li><a href=#aflibercept-in-combination-with-folfiri-for-metastatic-colorectal-cancer-a-randomized-phase-iii-trial>Aflibercept in Combination with FOLFIRI for Metastatic Colorectal Cancer: A Randomized Phase III Trial</a></li><li><a href=#ziv-aflibercept-zaltrap>Ziv-Aflibercept (Zaltrap)</a></li><li><a href=#ramucirumab-cyramza>Ramucirumab (Cyramza)</a></li><li><a href=#raise-trial>RAISE Trial</a></li><li><a href=#as-third-line-therapy>as third-line therapy</a><ol><li><a href=#regorafenib>regorafenib</a></li></ol></li><li><a href=#correct>CORRECT</a></li><li><a href=#subsequent-therapy>SUBSEQUENT THERAPY</a></li><li><a href=#in-older-adult-patients-and-those-with-a-poor-performance-status>in older adult patients and those with a poor performance status</a></li><li><a href=#phase-ii-prodige-20>phase II PRODIGE 20</a></li><li><a href=#avex-trial>AVEX trial</a><ol><li></li></ol></li></ol></nav></details></aside><a href=#anti-vegf-agents-in-metastatic-colorectal-cancer><h1 id=anti-vegf-agents-in-metastatic-colorectal-cancer><span class=hanchor arialabel=Anchor># </span>Anti-VEGF agents in metastatic colorectal cancer</h1></a><a href=#fellow-1-林協霆><h4 id=fellow-1-林協霆><span class=hanchor arialabel=Anchor># </span>Fellow 1 林協霆</h4></a><a href=#supervisor-黃國埕醫師><h4 id=supervisor-黃國埕醫師><span class=hanchor arialabel=Anchor># </span>Supervisor 黃國埕醫師</h4></a><hr><a href=#what-is-anti-vascular-endothelial-growth-factor-vegf><h2 id=what-is-anti-vascular-endothelial-growth-factor-vegf><span class=hanchor arialabel=Anchor># </span>What is anti-vascular endothelial growth factor (VEGF)</h2></a><p>:::columns</p><p><img src=https://i.imgur.com/b0wDlkS.png width=auto alt="Figure: height:450px"></p><p>:::split</p><ul><li>VEGFR-1,2,3</li><li>VEGF-A,B,C,D</li></ul><p>:::</p><hr><a href=#overview-of-angiogenesis-inhibitors><h2 id=overview-of-angiogenesis-inhibitors><span class=hanchor arialabel=Anchor># </span>Overview of angiogenesis inhibitors</h2></a><ul><li>bevacizumab (Avastin)</li><li>ziv-aflibercept (Zaltrap)</li><li>ramucirumab (Cyramza)</li><li>regorafenib (Stivarga)</li></ul><blockquote><p>Placental growth factor，PlGF</p></blockquote><p><img src=https://i.imgur.com/kfK6uf5.png width=auto alt="bg right:50% 90%"></p><hr><a href=#qucik-look-at-esmo-2023-for-mcrc><h1 id=qucik-look-at-esmo-2023-for-mcrc><span class=hanchor arialabel=Anchor># </span>Qucik Look at ESMO 2023 for mCRC</h1></a><hr><a href=#esmo-2023-mcrc><h3 id=esmo-2023-mcrc><span class=hanchor arialabel=Anchor># </span>ESMO 2023 mCRC</h3></a><a href=#1st-l><h4 id=1st-l><span class=hanchor arialabel=Anchor># </span>1st L</h4></a><p><img src=https://i.imgur.com/tGF8ESy.png width=auto alt="Figure: bg right:80% height:600px"></p><hr><a href=#esmo-2023-mcrc-1><h3 id=esmo-2023-mcrc-1><span class=hanchor arialabel=Anchor># </span>ESMO 2023 mCRC</h3></a><p>maintenance</p><p><img src=https://i.imgur.com/ExVIPLr.png width=auto alt="Figure: bg right:80% height:600px"></p><hr><a href=#esmo-2023-mcrc-2><h3 id=esmo-2023-mcrc-2><span class=hanchor arialabel=Anchor># </span>ESMO 2023 mCRC</h3></a><a href=#2nd-l><h4 id=2nd-l><span class=hanchor arialabel=Anchor># </span>2nd L</h4></a><p><img src=https://i.imgur.com/X3FLI9d.png width=auto alt="Figure: bg right:80% height:600px"></p><hr><a href=#esmo-2023-mcrc-3><h3 id=esmo-2023-mcrc-3><span class=hanchor arialabel=Anchor># </span>ESMO 2023 mCRC</h3></a><a href=#3rd-l><h4 id=3rd-l><span class=hanchor arialabel=Anchor># </span>3rd L</h4></a><p><img src=https://i.imgur.com/aRkoyFb.png width=auto alt="Figure: bg right:80% height:400px"></p><hr><a href=#what-should-i-consider-when-i-treat-patient-with-anti-vegfr><h5 id=what-should-i-consider-when-i-treat-patient-with-anti-vegfr><span class=hanchor arialabel=Anchor># </span>What should I consider when I treat patient with anti-VEGFR</h5></a><a href=#initial-assessment-surveillance-and-management-of-blood-pressure><h1 id=initial-assessment-surveillance-and-management-of-blood-pressure><span class=hanchor arialabel=Anchor># </span>Initial assessment, surveillance, and management of blood pressure</h1></a><hr><a href=#pretreatment-assessment-and-screening><h3 id=pretreatment-assessment-and-screening><span class=hanchor arialabel=Anchor># </span>Pretreatment assessment and screening</h3></a><ol><li>Standardized blood pressure measurements, preferably on two separate occasions</li><li>lipid panel, electrocardiogram)</li><li>Use this information to determine the appropriate intensity of monitoring and target for blood pressure control during therapy</li><li>Treat preexisting hypertension and address other comorbidities that might, through more attentive management, prolong life and support more aggressive cancer therapy</li></ol><a href=#monitoring-during-treatment><h3 id=monitoring-during-treatment><span class=hanchor arialabel=Anchor># </span>Monitoring during treatment</h3></a><ol><li>Actively monitor blood pressure throughout treatment with more frequent assessments during the first cycle (when the bulk of blood pressure elevation is expected to occur)</li><li>Monitoring every two to three weeks after the first cycle</li></ol><hr><a href=#risk-factors-for-adverse-consequences-of-high-blood-pressure-bp><h2 id=risk-factors-for-adverse-consequences-of-high-blood-pressure-bp><span class=hanchor arialabel=Anchor># </span>Risk factors for adverse consequences of high blood pressure (BP)</h2></a><ul><li>Systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg</li><li>Diabetes mellitus</li><li>Established CV disease including any history of:<ul><li>Ischemic stroke, cerebral hemorrhage, or transient ischemic attack</li><li>Myocardial infarction, angina, coronary revascularization, or heart failure</li><li>Peripheral artery disease</li><li>Retinal hemorrhages or exudates and papilledema</li></ul></li></ul><hr><a href=#established-or-subclinical-renal-disease-including><h3 id=established-or-subclinical-renal-disease-including><span class=hanchor arialabel=Anchor># </span>Established or subclinical renal disease including</h3></a><ul><li>Microalbuminuria or proteinuria (>30 mg/24 h)</li><li>Serum creatinine in men >1.5 mg/dL, women >1.4 mg/dL</li><li>Calculated or estimated glomerular filtration rate &lt;60 mL/min/1.73 m2</li><li>Subclinical organ damage previously documented by:</li><li>ECG or echocardiogram revealing left ventricular hypertrophy</li><li>Carotid ultrasound study revealing wall thickening or plaque</li></ul><hr><a href=#three-or-more-of-the-following-cv-risk-factors><h3 id=three-or-more-of-the-following-cv-risk-factors><span class=hanchor arialabel=Anchor># </span>Three or more of the following CV risk factors</h3></a><ul><li>Age (men >55 y, women >65 y)</li><li>Cigarette smoking</li><li>Dyslipidemia as measured by:<ul><li>Total cholesterol >190 mg/dL or</li><li>Low-density lipoprotein cholesterol >130 mg/dL or</li><li>High-density lipoprotein cholesterol (men &lt;40 mg/dL; women &lt;46 mg/dL) or</li><li>Triglyceride >150 mg/dL</li></ul></li><li>Fasting plasma glucose >100 mg/dL</li><li>Family history of premature CV disease (first-degree male relative age &lt;55 y or first-degree female relative &lt;65 y)</li><li>Abdominal obesity male waist circumference >40 in; female >35 in (in persons of East Asian ancestry: male waist circumference >35 in and for women >31 in)</li></ul><hr><a href=#bevacizumab-avastin><h3 id=bevacizumab-avastin><span class=hanchor arialabel=Anchor># </span>Bevacizumab (Avastin)</h3></a><ul><li>Mechanism: Binds to VEGF</li><li>Dosing: <code>5–15 mg/kg</code> IV every 14–21 d, temporarily hold for proteinuria<ul><li>Colorectal cancer, metastatic, in combination with fluorouracil-based chemotherapy (Avastin and bevacizumab biosimilars), first- or second-line therapy:</li><li>IV: 5 mg/kg every 2 weeks (in combination with bolus-IFL) or 10 mg/kg every 2 weeks (in combination with FOLFOX4).</li></ul></li><li>Mechanism: Binds to VEGF</li><li>Dosing: 5–15 mg/kg IV every 14–21 d, temporarily hold for proteinuria</li><li>PK/PD: T1/2 ∼20 d</li></ul><hr><a href=#warnings><h2 id=warnings><span class=hanchor arialabel=Anchor># </span>Warnings</h2></a><a href=#gi-perforation><h3 id=gi-perforation><span class=hanchor arialabel=Anchor># </span>GI Perforation</h3></a><ul><li>Severe, sometimes fatal, GI perforation reported;<ul><li>generally manifested as abdominal pain, nausea, vomiting, constipation, and fever.</li><li>Usually occurs within the first 50 days following initiation of bevacizumab.</li></ul></li><li>GI perforation c/w fistula formation and/or intra-abdominal abscess.</li></ul><hr><a href=#surgery-and-wound-healing-complications><h3 id=surgery-and-wound-healing-complications><span class=hanchor arialabel=Anchor># </span>Surgery and Wound Healing Complications</h3></a><ul><li>Wound healing and bleeding complications (including wound dehiscence)</li><li>Do not initiate bevacizumab therapy until ≥28 days following major surgery and after surgical incision has fully healed.</li><li>Discontinue bevacizumab ≥28 days prior to elective surgery.  Appropriate interval between discontinuance of bevacizumab and subsequent elective surgery not established, but consider long half-life of bevacizumab. (See Half-life under Pharmacokinetics.) Manufacturer recommends resuming therapy only after surgical incision has fully healed.</li><li>Discontinue bevacizumab permanently if wound dehiscence and wound healing complications requiring medical intervention occur.  (See Boxed Warning.)</li></ul><hr><a href=#hemorrhage><h3 id=hemorrhage><span class=hanchor arialabel=Anchor># </span>Hemorrhage</h3></a><ul><li>Severe, sometimes fatal, hemorrhagic events (e.g., hemoptysis, GI bleeding, hematemesis, CNS hemorrhage, epistaxis, vaginal bleeding) reported. (See Boxed Warning.)</li><li>Risk of severe or fatal pulmonary hemorrhage in patients with non-small cell lung cancer.  Serious or fatal pulmonary hemorrhage reported in 31% of patients with squamous cell histology and in 4% of patients with nonsquamous cell histology.</li><li>Risk of CNS hemorrhage in patients with NSCLC and CNS metastases.  Intracranial hemorrhage reported in patients with glioblastoma.</li><li>Mild hemorrhagic events, most commonly grade 1 epistaxis, also reported.</li><li>Do not administer to patients with recent hemoptysis (≥½ teaspoon of red blood).  If severe hemorrhage (i.e., requiring medical intervention) occurs, discontinue bevacizumab permanently.</li></ul><hr><a href=#sensitivity-reactions><h3 id=sensitivity-reactions><span class=hanchor arialabel=Anchor># </span>Sensitivity Reactions</h3></a><ul><li>Infusion Reactions</li><li>Infusion reactions (e.g., hypertension, hypertensive crisis associated with neurologic manifestations, wheezing, oxygen desaturation, grade 3 hypersensitivity, chest pain, headache, rigor, diaphoresis) reported.</li><li>Infuse initial doses slowly, increasing rate of infusion as tolerated. (See Rate of Administration under Dosage and Administration.)</li><li>If severe infusion reactions occur, interrupt infusion and administer appropriate medical therapy.  Adequate information on rechallenge not available.</li></ul><hr><a href=#thromboembolism><h3 id=thromboembolism><span class=hanchor arialabel=Anchor># </span>Thromboembolism</h3></a><ul><li><p>Serious, sometimes fatal, arterial thromboembolic events (e.g., cerebral infarction, TIA, MI, angina) reported.  Increased risk in patients with a history of arterial thromboembolism or patients >65 years of age.  Weigh risks against benefits of therapy.  Discontinue therapy permanently if severe arterial thromboembolic event occurs;  safety of resuming therapy after resolution of an arterial thromboembolic event not studied.</p></li><li><p>Grade 3 or 4 venous thromboembolic events (e.g., DVT, intra-abdominal venous thrombosis) reported.  Increased risk of developing second thromboembolic event reported in patients with metastatic colorectal cancer receiving bevacizumab with chemotherapy despite use of full-dose warfarin therapy following an initial venous thromboembolic event.</p></li></ul><hr><a href=#hypertension><h3 id=hypertension><span class=hanchor arialabel=Anchor># </span>Hypertension</h3></a><ul><li>Severe hypertension (grade 3 or 4) reported.</li><li>Monitor BP every 2–3 weeks during therapy.</li><li>If hypertension occurs, initiate appropriate antihypertensive therapy and monitor BP regularly.  Temporarily discontinue therapy in patients with severe hypertension not controlled with medical management.  Discontinue therapy permanently if hypertensive crisis or hypertensive encephalopathy occurs.  If therapy is discontinued because of hypertension, monitor BP at regular intervals thereafter.</li></ul><hr><a href=#reversible-posterior-leukoencephalopathy-syndrome-rpls><h3 id=reversible-posterior-leukoencephalopathy-syndrome-rpls><span class=hanchor arialabel=Anchor># </span>Reversible Posterior Leukoencephalopathy Syndrome (RPLS)</h3></a><ul><li>RPLS (a brain-capillary leak syndrome) reported.  May manifest with headache, seizure, lethargy, confusion, blindness, and other visual and neurologic disturbances; mild to severe hypertension also may occur.  Manifestations occurred from 16 hours to 1 year after initiation of bevacizumab.  Magnetic resonance imaging (MRI) is necessary to confirm diagnosis of RPLS.</li><li>Closely monitor and maintain strict control of BP during and following bevacizumab infusion.  If RPLS develops, discontinue bevacizumab and initiate treatment of hypertension as clinically indicated.  Symptoms usually lessen or resolve within days of drug discontinuance, but some patients have experienced ongoing neurologic sequelae.  Risk of reinitiating bevacizumab in patients previously experiencing RPLS not known.</li></ul><hr><a href=#proteinuria><h3 id=proteinuria><span class=hanchor arialabel=Anchor># </span>Proteinuria</h3></a><ul><li>Increased incidence and severity of proteinuria reported.  Severity ranges from clinically silent to nephrotic syndrome.  Proteinuria with findings of thrombotic microangiopathy on renal biopsy reported in patients receiving bevacizumab alone or in combination with other antineoplastic agents for various cancers.</li><li>Monitor patients for development or worsening of proteinuria with serial urinalysis.  Further assessment (e.g., 24-hour urine collection) recommended if ≥2+ urine dipstick reading occurs.  Interrupt bevacizumab therapy for moderate proteinuria (≥2 g per 24 hours); resume therapy when proteinuria is &lt;2 g per 24 hours.  Safety of continuing therapy in patients with moderate to severe proteinuria not known.</li><li>Discontinue bevacizumab permanently in patients with nephrotic syndrome.</li></ul><hr><a href=#ovarian-failure><h3 id=ovarian-failure><span class=hanchor arialabel=Anchor># </span>Ovarian Failure</h3></a><ul><li>Ovarian failure reported in premenopausal women receiving bevacizumab in combination with chemotherapy (i.e., modified FOLFOX6)</li><li>for adjuvant treatment of colorectal cancer.  Recovery of ovarian function occurred in 22% of patients following discontinuance of bevacizumab.  Long-term effects on fertility unknown.</li><li>Inform women of childbearing potential of risk of ovarian failure prior to initiating bevacizumab.</li></ul><a href=#neutropenia-and-infection><h3 id=neutropenia-and-infection><span class=hanchor arialabel=Anchor># </span>Neutropenia and Infection</h3></a><p>Severe (grade 3 or 4) neutropenia, febrile neutropenia, infection with severe neutropenia (sometimes fatal), and serious infections (e.g., pneumonia, catheter infections, wound infections) reported.</p><hr><a href=#chf><h3 id=chf><span class=hanchor arialabel=Anchor># </span>CHF</h3></a><ul><li>CHF reported; higher risk in patients also receiving or who had previously received anthracyclines.</li><li>Safety of continuation or resumption of bevacizumab in patients who develop cardiac dysfunction not studied.</li></ul><a href=#microangiopathic-hemolytic-anemia><h3 id=microangiopathic-hemolytic-anemia><span class=hanchor arialabel=Anchor># </span>Microangiopathic Hemolytic Anemia</h3></a><p>Microangiopathic hemolytic anemia reported in patients with solid tumors receiving bevacizumab and sunitinib
;  cases were reversible within 3 weeks following discontinuance of both drugs without other interventions.  Use of bevacizumab in combination with sunitinib is not recommended.</p><hr><a href=#ocular-effects><h3 id=ocular-effects><span class=hanchor arialabel=Anchor># </span>Ocular Effects</h3></a><ul><li>Permanent loss of vision,</li><li>endophthalmitis (infectious and sterile),</li><li>intraocular inflammation, retinal detachment, increased IOP, hemorrhage (including conjunctival, vitreous, or retinal hemorrhage), vitreous floaters, ocular hyperemia, and ocular pain or discomfort reported in patients receiving intravitreal injection of bevacizumab for treatment of various ocular disorders</li></ul><hr><a href=#as-first-line-therapy-bevacizumab-may-be-given-with><h2 id=as-first-line-therapy-bevacizumab-may-be-given-with><span class=hanchor arialabel=Anchor># </span>As first-line therapy, bevacizumab may be given with</h2></a><ul><li>FOLFOX, CAPEOX, or FOLFIRI</li><li>FOLFOXIRI in selected fit patients with cytoreduction as goal, and potentially in fit patients with mutated BRAF</li><li>fluoropyrimidines if aggressive treatments not tolerable</li></ul><hr><a href=#bevacizumab-plus-irinotecan-fluorouracil-and-leucovorin-for-metastatic-colorectal-cancer><h2 id=bevacizumab-plus-irinotecan-fluorouracil-and-leucovorin-for-metastatic-colorectal-cancer><span class=hanchor arialabel=Anchor># </span>Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</h2></a><a href=#nejm-2004><h4 id=nejm-2004><span class=hanchor arialabel=Anchor># </span>NEJM 2004</h4></a><p>:::columns</p><ul><li><code>Phase III</code> <code>Multi-center</code> <code>Double-blind</code></li><li>Number of patients: 813</li><li>Population:<ul><li>Previously untreated metastatic colorectal cancer</li></ul></li><li>Bevacizumab (5 mg/kg every two weeks)</li><li>Irinotecan, bolus fluorouracil, and leucovorin (IFL)</li><li>Treatment line: First-line</li></ul><p>:::split</p><table><thead><tr><th style=text-align:center>Endpoints</th><th style=text-align:center>IFL + Bevacizumab</th><th style=text-align:center>IFL + Placebo</th></tr></thead><tbody><tr><td style=text-align:center>PFS (months)</td><td style=text-align:center>10.6</td><td style=text-align:center>6.2</td></tr><tr><td style=text-align:center>RR (%)</td><td style=text-align:center>44.8</td><td style=text-align:center>34.8</td></tr><tr><td style=text-align:center>OS (months)</td><td style=text-align:center>20.3</td><td style=text-align:center>15.6</td></tr></tbody></table><p>:::</p><blockquote><p>Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., &mldr; & Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England journal of medicine, 350(23), 2335-2342.</p></blockquote><hr><a href=#adding-bevacizumab-to-chemotherapy-for-metastatic-colorectal-cancer-pooled-analysis-of-randomized-controlled-trials><h2 id=adding-bevacizumab-to-chemotherapy-for-metastatic-colorectal-cancer-pooled-analysis-of-randomized-controlled-trials><span class=hanchor arialabel=Anchor># </span>Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer: Pooled Analysis of Randomized Controlled Trials</h2></a><p>:::columns</p><ul><li>Design: Pooled analysis of individual patient data from randomized controlled trials (RCTs)</li><li>Number of patients: 3,763</li><li>Patients characteristics: Patients with metastatic colorectal cancer (mCRC)</li><li>Agent: Bevacizumab added to chemotherapy</li><li>Treatment line: First-line and second-line</li><li>Trial Name/NCT Number: Not reported</li></ul><p>:::split</p><table><thead><tr><th>Outcome</th><th>Hazard Ratio (HR)</th><th>95% Confidence Interval (CI)</th></tr></thead><tbody><tr><td>Overall Survival (OS)</td><td>0.80</td><td>0.71-0.90</td></tr><tr><td>Progression-free Survival (PFS)</td><td>0.57</td><td>0.46-0.71</td></tr><tr><td>Response Rate (RR)</td><td>Not reported</td><td></td></tr></tbody></table><p>:::</p><blockquote><p>Hurwitz, H. I., Tebbutt, N. C., Kabbinavar, F., Giantonio, B. J., Guan, Z. Z., Mitchell, L., &mldr; & Tabernero, J. (2013). Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. The oncologist, 18(9), 1004-1012.</p></blockquote><hr><ul><li>The addition of bevacizumab to chemotherapy resulted in statistically significant increases in OS and PFS for patients with mCRC.</li><li>The PFS benefit extended across the clinically relevant subgroups examined.</li><li>Bevacizumab treatment was associated with increased incidence rates of grade ≥3 hypertension, proteinuria, bleeding, wound-healing complications, gastrointestinal perforations, and thromboembolic events.</li><li>Other findings: Not reported</li></ul><a href=#summary><h3 id=summary><span class=hanchor arialabel=Anchor># </span>Summary</h3></a><ul><li>Results showed that the addition of bevacizumab to chemotherapy was associated with statistically significant increases in overall survival (OS) and progression-free survival (PFS) for patients with mCRC.</li><li>The PFS benefit extended across the clinically relevant subgroups examined.</li><li>However, bevacizumab treatment was also associated with increased incidence rates of several adverse events.</li></ul><hr><a href=#safety-and-efficacy-of-three-oxaliplatin-and-fluoropyrimidine-regimens-with-or-without-bevacizumab-as-first-line-treatment-for-metastatic-colorectal-cancer><h2 id=safety-and-efficacy-of-three-oxaliplatin-and-fluoropyrimidine-regimens-with-or-without-bevacizumab-as-first-line-treatment-for-metastatic-colorectal-cancer><span class=hanchor arialabel=Anchor># </span>Safety and Efficacy of Three Oxaliplatin and Fluoropyrimidine Regimens with or Without Bevacizumab as First-line Treatment for Metastatic Colorectal Cancer</h2></a><ul><li>Design: Randomized controlled trial</li><li>Number of patients: 150 (TREE-1 cohort) and 223 (TREE-2 cohort)</li><li>Patients characteristics: Patients with histologically documented metastatic or recurrent colorectal cancer (CRC) and no prior treatment for advanced disease</li><li>Agent: Oxaliplatin and fluoropyrimidine regimens (mFOLFOX6, bFOL, or CapeOx) with or without bevacizumab</li><li>Treatment line: First-line</li><li>Trial Name/NCT Number: Three Regimens of Eloxatin Evaluation (TREE-1 and TREE-2)</li></ul><hr><table><thead><tr><th>Outcome</th><th>TREE-1</th><th>TREE-2</th></tr></thead><tbody><tr><td>Overall Response Rate</td><td>mFOLFOX6: 41%<br>bFOL: 20%<br>CapeOx: 27%</td><td>mFOLFOX6 + bevacizumab: 52%<br>bFOL + bevacizumab: 39%<br>CapeOx + bevacizumab: 46%</td></tr><tr><td>Median Overall Survival (OS)</td><td>19.2 months</td><td>26.1 months</td></tr><tr><td>Median OS for all treated patients</td><td>18.2 months</td><td>23.7 months</td></tr></tbody></table><blockquote><p>Hochster, Howard S., et al. &ldquo;Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.&rdquo; Journal of Clinical Oncology 26.21 (2008): 3523-3529.</p></blockquote><hr><a href=#efficacy-and-safety-of-bevacizumab-in-metastatic-colorectal-cancer-patients><h2 id=efficacy-and-safety-of-bevacizumab-in-metastatic-colorectal-cancer-patients><span class=hanchor arialabel=Anchor># </span>Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer Patients</h2></a><p>:::columns</p><ul><li>Number: 1,401</li><li>Characteristics: Patients with metastatic colorectal cancer (MCRC)</li><li>Bevacizumab when added to first-line oxaliplatin-based chemotherapy</li><li>First-line</li><li>NCT00069045</li></ul><p>:::split</p><table><thead><tr><th>Outcomes</th><th>Bevacizumab Group</th><th>Placebo Group</th></tr></thead><tbody><tr><td>Progression-free survival (PFS)</td><td>9.4 months</td><td>8.0 months</td></tr><tr><td>Overall survival (OS)</td><td>21.3 months</td><td>19.9 months</td></tr><tr><td>Response rate (RR)</td><td>Not reported</td><td>Not reported</td></tr></tbody></table><p>:::</p><hr><a href=#irinotecan-regimens><h2 id=irinotecan-regimens><span class=hanchor arialabel=Anchor># </span>Irinotecan regimens</h2></a><p>:::columns</p><ul><li><code>Randomized</code>, <code>double-blind</code>, <code>placebo-controlled trial</code></li><li>813 patients with previously untreated metastatic colorectal cancer were enrolled, with 402 patients receiving IFL plus bevacizumab and 411 patients receiving IFL plus placebo.</li><li>Previously untreated metastatic colorectal cancer patients.</li></ul><p>:::split</p><ul><li>Bevacizumab in combination with irinotecan, bolus fluorouracil, and leucovorin (IFL).</li><li>Treatment line: First-line treatment of metastatic colorectal cancer.</li></ul><table><thead><tr><th>Treatment</th><th>Median Overall Survival (months)</th><th>Median Progression-Free Survival (months)</th><th>Response Rate</th></tr></thead><tbody><tr><td>IFL plus bevacizumab</td><td>20.3</td><td>10.6</td><td>44.8%</td></tr><tr><td>IFL plus placebo</td><td>15.6</td><td>6.2</td><td>34.8%</td></tr></tbody></table><p>:::</p><hr><a href=#in-the-tribe-study-for-bevfolfoxiri><h2 id=in-the-tribe-study-for-bevfolfoxiri><span class=hanchor arialabel=Anchor># </span>In the TRIBE study for Bev/FOLFOXIRI</h2></a><ol><li>Design: Open-label, multicentre, phase 3 randomized study.</li><li>Number of patients: 508 patients were enrolled.</li><li>Patients characteristics: Patients aged 18-70 years with ECOG performance status of 2 or less and aged 71-75 years with an ECOG performance status of 0 with unresectable metastatic colorectal cancer.</li><li>Agent: FOLFOXIRI plus bevacizumab or FOLFIRI plus bevacizumab.</li><li>Treatment line: Not reported.</li><li>Trial Name or NCT Number: NCT00719797.</li></ol><hr><p>:::columns</p><table><thead><tr><th>Treatment</th><th>Median Overall Survival (months)</th><th>Hazard Ratio (95% CI)</th></tr></thead><tbody><tr><td>FOLFOXIRI + bevacizumab</td><td>29.8</td><td>0.80 (0.65-0.98)</td></tr><tr><td>FOLFIRI + bevacizumab</td><td>25.8</td><td>Not reported</td></tr></tbody></table><p>:::split</p><table><thead><tr><th>Molecular Subgroup</th><th>Median Overall Survival (months)</th><th>Hazard Ratio (95% CI)</th></tr></thead><tbody><tr><td>RAS and BRAF wild-type</td><td>37.1</td><td>Not reported</td></tr><tr><td>RAS-mutation-positive</td><td>25.6</td><td>1.49 (1.11-1.99)</td></tr><tr><td>BRAF-mutation-positive</td><td>13.4</td><td>2.79 (1.75-4.46)</td></tr></tbody></table><p>:::</p><hr><a href=#in-ras-wt-left-sided-mcrc><h4 id=in-ras-wt-left-sided-mcrc><span class=hanchor arialabel=Anchor># </span>In RAS wt, Left-sided mCRC</h4></a><a href=#comparison-of-chemotherapy-plus-bevacizumab-vs-cetuximab-in-first-line-treatment-for-metastatic-colorectal-cancer><h2 id=comparison-of-chemotherapy-plus-bevacizumab-vs-cetuximab-in-first-line-treatment-for-metastatic-colorectal-cancer><span class=hanchor arialabel=Anchor># </span>Comparison of Chemotherapy plus Bevacizumab vs Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer</h2></a><ul><li><a href=/slides/fire rel=noopener class=internal-link data-src=/slides/fire>FIRE-3</a> : 28.7 month</li><li><a href=/calgb-swog rel=noopener class=internal-link data-src=/calgb-swog>CALGB-SWOG 80405</a> : 30 month</li><li><a href=/paradigm rel=noopener class=internal-link data-src=/paradigm>PARADIGM</a> 37.9 vs 34.3</li></ul><hr><a href=#fire-3><h2 id=fire-3><span class=hanchor arialabel=Anchor># </span>FIRE-3</h2></a><ul><li>Open-label, randomized, phase 3 trial</li><li>Single-center study in Germany and Austria</li><li>Patients were centrally randomized (1:1) to FOLFIRI plus cetuximab or FOLFIRI plus bevacizumab</li><li>Stratified according to ECOG performance status, number of metastatic sites, white blood cell count, and alkaline phosphatase concentration</li><li>592 patients with KRAS exon 2 wild-type tumors<ul><li>297 patients in the FOLFIRI plus cetuximab group</li><li>295 patients in the FOLFIRI plus bevacizumab group</li></ul></li><li>Stage IV, histologically confirmed colorectal cancer<ul><li>Eastern Cooperative Oncology Group (ECOG) performance status of 0-2</li><li>Estimated life expectancy of greater than 3 months</li></ul></li><li>Adequate organ function</li></ul><hr><a href=#treatment-line><h4 id=treatment-line><span class=hanchor arialabel=Anchor># </span>Treatment Line</h4></a><ul><li>First-line treatment of metastatic colorectal cancer</li></ul><a href=#comparison-of-two-groups><h2 id=comparison-of-two-groups><span class=hanchor arialabel=Anchor># </span>Comparison of Two Groups</h2></a><ul><li>Objective response rate: 62.0% (95% CI 56.2-67.5) in the cetuximab group vs. 58.0% (52.1-63.7) in the bevacizumab group (odds ratio 1.18, 95% CI 0.85-1.64; p=0.18)</li><li>Median progression-free survival: 10.0 months (95% CI 8.8-10.8) in the cetuximab group vs. 10.3 months (9.8-11.3) in the bevacizumab group (hazard ratio [HR] 1.06, 95% CI 0.88-1.26; p=0.55)</li><li>Median overall survival: 28.7 months (95% CI 24.0-36.6) in the cetuximab group vs. 25.0 months (22.7-27.6) in the bevacizumab group (HR 0.77, 95% CI 0.62-0.96; p=0.017)</li></ul><a href=#other-findings><h2 id=other-findings><span class=hanchor arialabel=Anchor># </span>Other Findings</h2></a><ul><li>Safety profiles were consistent with the known side-effects of the study drugs</li><li>The most common grade 3 or worse adverse events in both treatment groups were haematotoxicity, skin reactions, and diarrhea</li></ul><a href=#summary-1><h2 id=summary-1><span class=hanchor arialabel=Anchor># </span>Summary</h2></a><p>This randomized controlled trial compared the effectiveness of cetuximab and bevacizumab when added to FOLFIRI as first-line treatment for metastatic colorectal cancer in patients with KRAS exon 2 wild-type tumors. While the proportion of patients who achieved an objective response did not significantly differ between the two groups, patients treated with FOLFIRI plus cetuximab had longer overall survival compared to those treated with FOLFIRI plus bevacizumab. The safety profiles were consistent with the known side-effects of the study drugs. These findings suggest that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.</p><hr><a href=#cetuximab-vs-bevacizumab-in-combination-with-chemotherapy-as-initial-biologic-therapy-for-advanced-or-metastatic-colorectal-cancer><h2 id=cetuximab-vs-bevacizumab-in-combination-with-chemotherapy-as-initial-biologic-therapy-for-advanced-or-metastatic-colorectal-cancer><span class=hanchor arialabel=Anchor># </span>Cetuximab vs Bevacizumab in Combination with Chemotherapy as Initial Biologic Therapy for Advanced or Metastatic Colorectal Cancer</h2></a><ul><li>Multi-center Randomized 1137 patients</li><li>Patients with previously untreated advanced or metastatic colorectal cancer<ul><li>Tumors were KRAS wild-type (wt)</li></ul></li><li>Cetuximab or bevacizumab</li><li>Chemotherapy regimens: mFOLFOX6 or FOLFIRI</li><li>First-line treatment</li></ul><a href=#results><h2 id=results><span class=hanchor arialabel=Anchor># </span>Results</h2></a><ul><li>No significant difference in overall survival between cetuximab-chemotherapy group and bevacizumab-chemotherapy group (HR = 0.88, 95% CI, 0.77-1.01; P = .08)</li><li>No significant difference in progression-free survival between cetuximab-chemotherapy group and bevacizumab-chemotherapy group (HR = 0.95, 95% CI, 0.84-1.08; P = .45)</li><li>No significant difference in overall response rate between cetuximab and bevacizumab (difference = 4.4%, 95% CI, 1.0%-9.0%, P = .13)</li></ul><a href=#other-findings-1><h2 id=other-findings-1><span class=hanchor arialabel=Anchor># </span>Other findings</h2></a><ul><li>Median overall survival was 30.0 months in the cetuximab-chemotherapy group and 29.0 months in the bevacizumab-chemotherapy group</li><li>Response rates were not significantly different between the two groups</li></ul><a href=#summary-2><h2 id=summary-2><span class=hanchor arialabel=Anchor># </span>Summary</h2></a><p>The study aimed to determine whether the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer. The results showed that there was no significant difference in overall survival, progression-free survival, or overall response rate between the cetuximab-chemotherapy group and the bevacizumab-chemotherapy group. The study suggests that the optimal choice of the initial biologic therapy in previously untreated patients is unknown.</p><hr><a href=#paradigm><h2 id=paradigm><span class=hanchor arialabel=Anchor># </span>PARADIGM</h2></a><p>:::columns</p><ul><li>Open-label</li><li>Multicenter</li><li>Randomized</li><li>Number of patients:</li><li>823 patients</li><li>Patient characteristics:</li><li>Chemotherapy-naive RAS WT metastatic colorectal cancer (mCRC)</li><li>Left-sided primary tumors</li></ul><p>:::split</p><p><img src=https://i.imgur.com/wsY6DW0.png width=auto alt="Figure: height:450px"></p><p>:::</p><hr><a href=#as-maintenance-therapy-continued-use-of-bevacizumab-in-patients-with-metastatic-colorectal-cancer-progressing-after-standard-first-line-bevacizumab-based-treatment><h2 id=as-maintenance-therapy-continued-use-of-bevacizumab-in-patients-with-metastatic-colorectal-cancer-progressing-after-standard-first-line-bevacizumab-based-treatment><span class=hanchor arialabel=Anchor># </span>As maintenance therapy: Continued use of bevacizumab in patients with metastatic colorectal cancer progressing after standard first-line bevacizumab-based treatment</h2></a><ul><li><p>Design</p><ul><li>Open-label, phase 3 study</li><li>Multi-center study in 220 centers in 15 countries</li><li>Randomized controlled trial</li><li>Patients were randomly assigned in a 1:1 ratio to second-line chemotherapy with or without bevacizumab</li></ul></li><li><p>Number of Patients</p><ul><li>820 patients in total<ul><li>409 patients were assigned to bevacizumab plus chemotherapy</li><li>411 patients were assigned to chemotherapy alone</li></ul></li></ul></li><li><p>Histologically confirmed metastatic colorectal cancer</p><ul><li>Patients progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy</li></ul></li></ul><a href=#agent><h2 id=agent><span class=hanchor arialabel=Anchor># </span>Agent</h2></a><ul><li>Bevacizumab plus standard second-line chemotherapy</li><li>Choice between oxaliplatin-based or irinotecan-based second-line chemotherapy depended on the first-line regimen (switch of chemotherapy)</li><li>Second-line treatment after progression on first-line bevacizumab plus chemotherapy</li></ul><hr><a href=#comparison-of-two-groups-1><h2 id=comparison-of-two-groups-1><span class=hanchor arialabel=Anchor># </span>Comparison of Two Groups</h2></a><table><thead><tr><th>Outcome</th><th>Bevacizumab plus chemotherapy</th><th>Chemotherapy alone</th></tr></thead><tbody><tr><td>Median overall survival (months)</td><td>11.2 (95% CI 10.4-12.2)</td><td>9.8 (95% CI 8.9-10.7)</td></tr><tr><td>Hazard ratio</td><td>0.81</td><td></td></tr><tr><td>Unstratified log-rank test p-value</td><td>0.0062</td><td></td></tr><tr><td>Grade 3-5 bleeding or hemorrhage</td><td>8 (2%)</td><td>1 (&lt;1%)</td></tr><tr><td>Gastrointestinal perforation</td><td>7 (2%)</td><td>3 (&lt;1%)</td></tr><tr><td>Venous thromboembolisms</td><td>19 (5%)</td><td>12 (3%)</td></tr></tbody></table><a href=#other-findings-2><h2 id=other-findings-2><span class=hanchor arialabel=Anchor># </span>Other Findings</h2></a><ul><li>Maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond disease progression has clinical benefits in patients with metastatic colorectal cancer</li><li>Grade 3-5 bleeding or hemorrhage, gastrointestinal perforation, and venous thromboembolisms were more common in the bevacizumab plus chemotherapy group than in the chemotherapy alone group</li><li>The most frequently reported grade 3-5 adverse events were neutropenia, diarrhea, and asthenia</li><li>Treatment-related deaths were reported for four patients in the bevacizumab plus chemotherapy group and three in the chemotherapy alone group</li></ul><hr><a href=#summary-3><h2 id=summary-3><span class=hanchor arialabel=Anchor># </span>Summary</h2></a><p>This randomized controlled trial investigated the use of bevacizumab plus standard second-line chemotherapy in patients with metastatic colorectal cancer who had progressed after first-line bevacizumab-based treatment. The trial found that maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond disease progression had clinical benefits, resulting in a median overall survival of 11.2 months compared to 9.8 months with chemotherapy alone. However, there were more adverse events in the bevacizumab plus chemotherapy group, including bleeding or hemorrhage, gastrointestinal perforation, and venous thromboembolisms. Treatment-related deaths were also reported in both groups</p><hr><a href=#comparison-of-chemotherapy-plus-bevacizumab-vs-cetuximab-in-second-line-treatment-for-metastatic-colorectal-cancer><h2 id=comparison-of-chemotherapy-plus-bevacizumab-vs-cetuximab-in-second-line-treatment-for-metastatic-colorectal-cancer><span class=hanchor arialabel=Anchor># </span>Comparison of Chemotherapy plus Bevacizumab vs Cetuximab in Second-Line Treatment for Metastatic Colorectal Cancer</h2></a><ul><li><p>Phase 2 trial Open-label Multicenter Randomized 132 patients</p></li><li><p>Disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer</p></li><li><p>47 women and 85 men</p></li><li><p>Median age, 63.0 years [range, 33.0-84.0 years]</p></li><li><p>74 patients with an Eastern Cooperative Oncology Group performance status of 0, 54 patients with a performance status of 1, and 4 patients with unknown performance status</p></li><li><p>Arm A: FOLFIRI or modified FOLFOX6 plus bevacizumab</p></li><li><p>Arm B: FOLFIRI or modified FOLFOX6 plus cetuximab</p></li><li><p>Second-line treatment</p></li><li><p>PRODIGE18 (Partenariat de Recherche en Oncologie DIGEstive) study</p></li></ul><a href=#comparison-of-two-groups-2><h3 id=comparison-of-two-groups-2><span class=hanchor arialabel=Anchor># </span>Comparison of Two Groups</h3></a><table><thead><tr><th>Endpoint</th><th>Arm A</th><th>Arm B</th></tr></thead><tbody><tr><td>4-month PFS rate</td><td>80.3% (95% CI, 68.0%-88.3%)</td><td>66.7% (95% CI, 53.6%-76.8%)</td></tr><tr><td>Median PFS</td><td>7.1 months (95% CI, 5.7-8.2 months)</td><td>5.6 months (95% CI, 4.2-6.5 months)</td></tr><tr><td>Hazard ratio (PFS)</td><td>0.71 (95% CI, 0.50-1.02)</td><td>Not reported</td></tr><tr><td>Median OS</td><td>15.8 months (95% CI, 9.5-22.3 months)</td><td>10.4 months (95% CI, 7.0-16.2 months)</td></tr><tr><td>Hazard ratio (OS)</td><td>0.69 (95% CI, 0.46-1.04)</td><td>Not reported</td></tr><tr><td>Objective response rate</td><td>Not reported</td><td>Not reported</td></tr></tbody></table><a href=#other-findings-3><h3 id=other-findings-3><span class=hanchor arialabel=Anchor># </span>Other Findings</h3></a><ul><li>A central analysis of KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), and BRAF (V600) was performed for 95 tumor samples</li><li>81 patients had wild-type KRAS and wild-type NRAS tumors</li></ul><a href=#summary-4><h3 id=summary-4><span class=hanchor arialabel=Anchor># </span>Summary</h3></a><p>The PRODIGE18 study evaluated the use of chemotherapy plus bevacizumab vs cetuximab for patients with progression of metastatic colorectal cancer after bevacizumab plus chemotherapy. The trial showed a nonsignificant difference but favored continuation of bevacizumab with chemotherapy crossover for patients with wild-type RAS metastatic colorectal cancer that progressed with first-line bevacizumab plus chemotherapy. The 4-month PFS rate was 80.3% in arm A and 66.7% in arm B, and the median PFS was 7.1 months in arm A and 5.6 months in arm B. The median overall survival was 15.8 months in arm A and 10.4 months in arm B. A central analysis of KRAS, NRAS, and BRAF was performed for 95 tumor samples, and 81 patients had wild-type KRAS and wild-type NRAS tumors.</p><hr><a href=#bebyp-trial><h2 id=bebyp-trial><span class=hanchor arialabel=Anchor># </span>BEBYP trial</h2></a><p>which randomly assigned 185 patients undergoing first-line fluoropyrimidine-plus bevacizumab chemotherapy to second-line FOLFOX or FOLFIRI with or without bevacizumab [111]. Accrual to the trial was prematurely stopped when the results of the TML trial became known. Median PFS was significantly improved by continuation of bevacizumab with the second-line regimen (median 6.8 versus 5 months), although the differences in ORRs to the second-line regimen (17 versus 21 percent), and DCRs overall (58 versus 70 percent) were not statistically significant.</p><blockquote><p>Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol. 2015;26(4):724-730. doi:10.1093/annonc/mdv012</p></blockquote><hr><a href=#whether-to-switch-to-cetuximab-or-continue-with-second-line-bevacizumab-in-patients-with-ras-wild-type-tumors-progressing-on-first-line-bevacizumab><h2 id=whether-to-switch-to-cetuximab-or-continue-with-second-line-bevacizumab-in-patients-with-ras-wild-type-tumors-progressing-on-first-line-bevacizumab><span class=hanchor arialabel=Anchor># </span>whether to switch to cetuximab or continue with second-line bevacizumab in patients with RAS wild-type tumors progressing on first-line bevacizumab</h2></a><p>was addressed in the phase II PRODIGE 18 trial [112]. Continuation with bevacizumab was associated with a numerically higher, but not statistically significant, median PFS (7.1 versus 5.6 months, p = 0.06) and OS (15.8 versus 10.4 months, p = 0.08) compared with cetuximab plus chemotherapy. These results favor continuation of bevacizumab with an alternative chemotherapy backbone in patients who progress with first-line bevacizumab plus chemotherapy.</p><blockquote><p>Hiret S, Borg C, Bertaut A, et al. Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI). JCO. 2016;34(15_suppl):3514-3514. doi:10.1200/JCO.2016.34.15_suppl.3514</p></blockquote><hr><a href=#aflibercept-in-combination-with-folfiri-for-metastatic-colorectal-cancer-a-randomized-phase-iii-trial><h2 id=aflibercept-in-combination-with-folfiri-for-metastatic-colorectal-cancer-a-randomized-phase-iii-trial><span class=hanchor arialabel=Anchor># </span>Aflibercept in Combination with FOLFIRI for Metastatic Colorectal Cancer: A Randomized Phase III Trial</h2></a><ul><li>Design: randomized, double-blind, placebo-controlled phase III trial</li><li>Number of patients: 1226 patients (612 received aflibercept and 614 received placebo)</li><li>Patients characteristics: metastatic colorectal cancer previously treated with oxaliplatin, including patients who received prior bevacizumab</li><li>Agent: Aflibercept (also known as ziv-aflibercept in the United States) in combination with FOLFIRI</li><li>Treatment line: second-line or later</li><li>Trial Name (if provided) or NCT Number: NCT00561470</li></ul><table><thead><tr><th>Group</th><th>Progression-free survival (PFS)</th><th>Overall survival (OS)</th><th>Response rate (RR)</th></tr></thead><tbody><tr><td>Aflibercept + FOLFIRI</td><td>Median PFS of 6.90 months</td><td>Median OS of 13.50 months</td><td>19.8%</td></tr><tr><td>Placebo + FOLFIRI</td><td>Median PFS of 4.67 months</td><td>Median OS of 12.06 months</td><td>11.1%</td></tr></tbody></table><ul><li>Other findings in this trial:<ul><li>Aflibercept significantly improved PFS and OS compared to placebo</li><li>Aflibercept also showed a consistent benefit across prespecified subgroup analyses, including bevacizumab pretreated patients</li><li>Adverse effects reported with aflibercept combined with FOLFIRI included anti-vascular endothelial growth factor effects and increased incidence of some chemotherapy-related toxicities</li></ul></li><li>Summary: The addition of aflibercept to FOLFIRI significantly improved overall survival and progression-free survival in patients with metastatic colorectal cancer previously treated with oxaliplatin, including those who received prior bevacizumab. However, the combination also resulted in increased toxicity.</li></ul><hr><a href=#ziv-aflibercept-zaltrap><h2 id=ziv-aflibercept-zaltrap><span class=hanchor arialabel=Anchor># </span>Ziv-Aflibercept (Zaltrap)</h2></a><ul><li>Dosing: 4 mg/kg IV every 2 wks. No renal or hepatic dose adjustments recommended</li><li>PK/PD: T1/2 ∼6 d</li><li>AEs: GI perforation (BBW), hemorrhage (BBW), impaired wound healing (BBW), proteinuria, HTN, thromboembolism, ↑ LFTs</li><li>DDI: Contraindicated w/ clozapine (↑ risk of agranulocytosis)</li><li>Clinical pearls: Monitor CBC, urine protein, BP, & signs of bleeding. Hold Rx at least 4 wks prior & 4 wks after major elective surgery</li></ul><hr><hr><ul><li>There are no randomized trials directly comparing second-line bevacizumab and aflibercept in patients who progressed on first-line bevacizumab.</li><li>Data are available from a multicenter retrospective analysis of 681 patients treated with second-line aflibercept (n = 326) or bevacizumab (n = 355) after progressing on first-line bevacizumab; 81 percent had RAS-mutated tumors [116], and it was concluded that after adjusting for age, performance status, PFS of first-line therapy, primary tumor location, metastasis location, and RAS/BRAF status, the use of bevacizumab was associated with longer PFS and OS (HR 0.71, 95% CI 0.59-0.86), as well as better tolerability.</li></ul><hr><a href=#ramucirumab-cyramza><h2 id=ramucirumab-cyramza><span class=hanchor arialabel=Anchor># </span>Ramucirumab (Cyramza)</h2></a><ul><li>Mechanism: Binds to VEGFR2</li><li>Dosing: Dosing dependent on dz; colorectal/gastric: 8 mg/kg IV every 2 wks as part of combination therapy; NSCLC 10 mg/kg every 21 d w/ docetaxel</li><li>PK/PD: T1/2 ∼14 d</li><li>AEs: HTN, diarrhea, proteinuria, neutropenia, anemia, infusion-related rxns</li><li>DDI: No known pathways of metabolism</li><li>Clinical pearls: Premedications required; pts w/ HTN should be controlled prior to administration & BPs monitored closely</li></ul><hr><a href=#raise-trial><h2 id=raise-trial><span class=hanchor arialabel=Anchor># </span>RAISE Trial</h2></a><ul><li>Design:<ul><li>Multicentre, randomised, double-blind, phase 3 RAISE trial</li><li>Randomised (1:1) via a centralised, interactive voice-response system to receive 8 mg/kg intravenous ramucirumab plus FOLFIRI or matching placebo plus FOLFIRI every 2 weeks until disease progression, unacceptable toxic effects, or death.</li><li>Stratified by region, KRAS mutation status, and time to disease progression after starting first-line treatment.</li></ul></li><li>Number of patients: 1072 patients (536 in each group)</li><li>Patients characteristics: Patients with metastatic colorectal cancer with disease progression during or within 6 months of the last dose of first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.</li><li>Agent: Ramucirumab</li><li>Treatment line: Second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan)</li><li>Trial Name: RAISE trial (NCT01183780)</li><li>Comparison of two groups in a markdown table:</li></ul><hr><table><thead><tr><th>Outcome Measures</th><th>Ramucirumab + FOLFIRI</th><th>Placebo + FOLFIRI</th></tr></thead><tbody><tr><td>Median overall survival (months)</td><td>13.3 (95% CI 12.4-14.5)</td><td>11.7 (10.8-12.7)</td></tr><tr><td>Hazard ratio</td><td>0.844 95% CI 0.730-0.976</td><td>-</td></tr><tr><td>Log-rank p-value</td><td>0.0219</td><td>-</td></tr><tr><td>Neutropenia (≥Grade 3)</td><td>203 (38%)</td><td>123 (23%)</td></tr><tr><td>Febrile neutropenia incidence</td><td>18 (3%)</td><td>13 (2%)</td></tr><tr><td>Hypertension (≥Grade 3)</td><td>59 (11%)</td><td>15 (3%)</td></tr><tr><td>Diarrhoea (≥Grade 3)</td><td>57 (11%)</td><td>51 (10%)</td></tr><tr><td>Fatigue (≥Grade 3)</td><td>61 (12%)</td><td>41 (8%)</td></tr></tbody></table><ul><li>Other findings in this trial:<ul><li>Survival benefit was consistent across subgroups of patients who received ramucirumab plus FOLFIRI.</li></ul></li><li>Summary:
The RAISE trial shows that ramucirumab plus FOLFIRI significantly improves overall survival compared to FOLFIRI with placebo in patients with metastatic colorectal cancer who had disease progression during or within 6 months of the last dose of first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. The survival benefit was consistent across subgroups of patients who received ramucirumab plus FOLFIRI.</li></ul><hr><ul><li>Based on these results, ramucirumab was approved in April 2015 for use in combination with FOLFIRI for the treatment of mCRC in patients whose disease has progressed on a first-line bevacizumab-, oxaliplatin-, and fluoropyrimidine-containing regimen.</li><li>However, given this modest degree of benefit, the expense of this agent [118], and the competing data indicating benefit from continuation of second-line bevacizumab in this same setting, we do not consider ramucirumab the agent of choice if continued VEGF inhibition beyond first-line progression is considered.</li><li>for patients who are fast progressors in bevacizumab-based first-line therapy, consider either ziv-aflibercept or ramucirumab plus FOLFIRI (ESMO Grade B, Level II)</li><li>for patients who progress on non-irinotecan-containing therapy, either ziv-aflibercept or ramucirumab plus either FOLFORI or irinotecan may be considered (NCCN Category 2A)</li><li>bevacizumab preferred over ziv-aflibercept and ramucirumab</li></ul><hr><a href=#as-third-line-therapy><h2 id=as-third-line-therapy><span class=hanchor arialabel=Anchor># </span>as third-line therapy</h2></a><a href=#regorafenib><h3 id=regorafenib><span class=hanchor arialabel=Anchor># </span>regorafenib</h3></a><hr><a href=#correct><h2 id=correct><span class=hanchor arialabel=Anchor># </span>CORRECT</h2></a><hr><a href=#subsequent-therapy><h2 id=subsequent-therapy><span class=hanchor arialabel=Anchor># </span>SUBSEQUENT THERAPY</h2></a><ul><li>Activity in refractory mCRC was initially shown in the CORRECT trial, in which 760 patients who had progressed after multiple standard therapies were randomly assigned to best supportive care plus regorafenib (160 mg orally once daily for three of every four weeks) or placebo [156].</li><li>Patients assigned to regorafenib had a modest though statistically significant improvement in median overall survival (OS; 6.4 versus 5 months, hazard ratio [HR] 0.77, 95% CI 0.64-0.94), and the difference in progression-free survival (PFS), while very small, was statistically significant (HR 0.49, median 1.9 versus 1.7 months).</li><li>While the disease control rate (DCR) was higher with regorafenib (41 versus 15 percent), only five patients (1 percent) experienced a partial response.</li><li>The group receiving regorafenib had more grade 3 or 4 hand-foot skin reaction (17 versus 0.4 percent), fatigue (10 versus 5 percent), hypertension (7 versus 1 percent), diarrhea (7 versus 1 percent), and skin rash (6 versus 0 percent).</li><li>Fatal hepatic failure occurred in 1.6 percent of patients treated with regorafenib versus 0.4 percent in the placebo group. (See &ldquo;Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects&rdquo; and &ldquo;Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects&rdquo;.)</li></ul><hr><ul><li><p>Benefit for regorafenib monotherapy was confirmed in the multicenter CONCUR trial, in which 204 Asian patients with mCRC who progressed after standard therapies were randomly assigned to regorafenib (160 mg daily for 21 of every 28 days) or placebo [157].</p></li><li><p>Regorafenib was associated with a significantly longer median PFS (3.2 versus 1.7 months) and OS (8.8 versus 6.3 months).</p></li><li><p>As was seen in the CORRECT trial, the DCR was significantly higher with regorafenib (51 versus 7 percent), although only six patients (4 percent) achieved a partial response (versus none in the placebo group).</p></li><li><p>The initial approved dose of regorafenib (160 mg daily for 21 days of every 28-day cycle) may be too high for many patients.</p></li><li><p>In the phase II ReDOS trial, a weekly dose escalating strategy (starting with 80 mg daily, escalating weekly in the absence of treatment-related toxicity to a target of 160 mg daily) allowed more patients to initiate the third cycle of therapy compared with starting at 160 mg per day (43 versus 26 percent) [167].</p></li><li><p>Median OS also trended better in the dose escalation cohort (9.8 versus 6 months), and toxicity was more favorable.</p></li></ul><hr><a href=#in-older-adult-patients-and-those-with-a-poor-performance-status><h2 id=in-older-adult-patients-and-those-with-a-poor-performance-status><span class=hanchor arialabel=Anchor># </span>in older adult patients and those with a poor performance status</h2></a><ul><li>In a pooled analysis of data from four randomized trials, the magnitude of benefit for the addition of bevacizumab to fluoropyrimidine-containing chemotherapy was similar albeit modest across all age groups (&lt;65, ≥65, ≥70) [37].</li><li>For the older age group, the median OS benefit from adding bevacizumab was only 3.3 months (median 17.4 versus 14.1 months, HR 0.79, 95% CI 0.66-0.93).</li><li>Bleeding, hypertension, proteinuria, ATEs, venous thromboembolic events, wound-healing complications, fistulae, gastrointestinal perforation, and congestive heart failure were all more common in bevacizumab-treated patients.</li><li>Among individuals 70 and older, the risk an arterial thrombotic event was twofold higher in the bevacizumab group (6.7 versus 3.2 percent).</li></ul><hr><a href=#phase-ii-prodige-20><h2 id=phase-ii-prodige-20><span class=hanchor arialabel=Anchor># </span>phase II PRODIGE 20</h2></a><ul><li>The randomized phase II PRODIGE 20 study of chemotherapy (short-term infusional FU plus LV alone or with oxaliplatin or irinotecan) with or without bevacizumab in individuals aged 75 or older, the addition of bevacizumab was associated with only a trend toward improved PFS (9.7 versus 7.8 months, HR 0.79, 95% CI 0.53-1.17) and OS (median 21.7 versus 19.8 months, HR 0.73, 95% CI 0.48-1.11) but significantly higher rate of grade 3 or 4 arterial hypertension (14 versus 6 percent) [45].</li></ul><hr><a href=#avex-trial><h2 id=avex-trial><span class=hanchor arialabel=Anchor># </span>AVEX trial</h2></a><ul><li>Similarly, in the multi-center AVEX trial, 280 patients age 70 or older with previously untreated mCRC were randomly assigned to capecitabine (1000 mg/m2 twice daily on days 1 to 14 every 21 days) with or without bevacizumab (7.5 mg/kg on day 1 every 21 days) [44].</li><li>Combined therapy was associated with significantly longer median PFS (the primary endpoint, 9.1 versus 5.1 months) and a non-significant trend toward longer OS (median 21 versus 17 months).</li><li>However, there were significantly more events leading to treatment discontinuation in the bevacizumab arm (25 versus 15 percent), and higher rates of all-grade hemorrhage (25 versus 7 percent), hypertension (19 versus 5 percent), and venous thromboembolic events (12 versus 5 percent, grade 3 or higher, 8 versus 4 percent).</li><li>There were six ATEs in the combined therapy group, compared with three with capecitabine monotherapy (4 versus 2 percent).</li><li>Although rates of grade 5 (fatal) toxicities were not higher with bevacizumab (8.2 versus 11.8 percent with capecitabine alone), they were higher than expected in both groups.</li></ul><hr><ul><li>The combination of capecitabine and bevacizumab is a good option for older adult patients.</li><li>Caution (and informed consent) is warranted when prescribing bevacizumab in combination with chemotherapy for older adult patients with a history of atherosclerotic cardiovascular disease.</li><li>The risks probably outweigh the benefits in patients with a history of stroke or myocardial infarction within the preceding 6 to 12 months, or a history of thromboembolic disease, and the drug is contraindicated in patients with severe uncontrolled hypertension.</li></ul><hr><a href=#the-end><h4 id=the-end><span class=hanchor arialabel=Anchor># </span>The End</h4></a><a href=#thank-you-for-your-attention><h1 id=thank-you-for-your-attention><span class=hanchor arialabel=Anchor># </span>Thank you for your attention</h1></a><a href=#_have-a-nice-day_><h1 id=_have-a-nice-day_><span class=hanchor arialabel=Anchor># </span><em>Have a nice day</em></h1></a><img src=https://i.imgur.com/yp5eb3i.png alt="Example Image" class=RLQ></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li>🤭沒有找到反向連結</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>